SW
ASND icon

SVB Wealth’s Ascendis Pharma A/S ASND Stock Holding History

SVB Wealth’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18
Closed -$2.81K – 559
2025
Q1 		$2.81K Buy
+18
New +$2.57K ﹤0.01% 1154
2021
Q2 		– Sell
-2,000
Closed -$258K – 992
2021
Q1 		$258K Buy
+2,000
New +$304K ﹤0.01% 752

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SVB Wealth's ASND Position: Q2 2025 in Review

SVB Wealth sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 18 shares — an estimated $2.81K sold.

SVB Wealth first reported a position in ASND in Q1 2021 and held it in 2 quarters. The position peaked at $258K in Q1 2021. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

  • SVB Wealth reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
  • SVB Wealth sold 18 Ascendis Pharma A/S shares in Q2 2025, an estimated $2.81K.
  • SVB Wealth first reported a position in Ascendis Pharma A/S in Q1 2021 and held it in 2 quarters.
  • SVB Wealth's Ascendis Pharma A/S position peaked at $258K in Q1 2021.
  • 247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.